Niki BioSolutions, Inc. (APM) Form 8-K — Oct 13, 2026
Niki BioSolutions, Inc. appointed Thomas Freeburg as Chief Financial Officer effective September 1, 2026, under a two-year employment agreement disclosed in an 8-K filed October 13, 2026. Freeburg was previously CFO of Interpace Biosciences (NASDAQ: IDXG) and is a CPA with reporting experience at Coach/Tapestry and Scholastic. Freeburg will receive a $250,000 base salary (with $25,000 deferred until the company raises $3,000,000 in cumulative funding), a bonus of up to 50% of salary, and 50,000 stock options at $8.83 per share, with an additional 25,000 options vesting fully on a change in control.
Key figures
- Term Years
- 2
- Base Salary
- 250000
- Stock Options
- 75000
- Deferred Salary
- 25000
- Option Exercise Price
- 8.83
- Annual Bonus Max Percent
- 50
- Deferred Salary Trigger
- 3000000
- Salary Increase Trigger
- 5000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.